



(51) International Patent Classification:

A61K 31/506 (2006.01) A61K 45/06 (2006.01)
A61K 31/519 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2025/018376

(22) International Filing Date:

04 March 2025 (04.03.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/561,041	04 March 2024 (04.03.2024)	US
63/673,543	19 July 2024 (19.07.2024)	US
63/765,206	28 February 2025 (28.02.2025)	US

(71) Applicant: **BLUEPRINT MEDICINES CORPORATION** [US/US]; 45 Sidney Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **HOUSE, Nealia C.M.**; 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **BROWN, Victoria E.**; 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **CHEN, Maxine M.**; 45 Sidney Street, Cam-

bridge, Massachusetts 02139 (US). **FAIA, Kerrie L.**; 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **MUTHUSWAMY, Lakshmi B.**; 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **RIBICH, Scott**; 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **CHOI, Yoon Jong**; 45 Sidney Street, Cambridge, Massachusetts 02139 (US).

(74) Agent: **KAVANAUGH, Theresa C.** et al.; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept./7th Fl., Boston, Massachusetts 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: CDK2 INHIBITORS FOR TREATMENT OF CANCER




FIG. 2E

(57) Abstract: The present disclosure provides improved methods of treating endometrial cancer or ovarian cancer in a subject using levels of combinations of biomarkers as predictive markers for response to CDK2 inhibitors and combinations with CDK2 inhibitors.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (*Art. 21(3)*)
- with sequence listing part of description (*Rule 5.2(a)*)